Overview
CagriSema is a research-grade peptide compound that has attracted significant attention in the scientific community for its role in metabolic regulation. Co-formulation of cagrilintide (amylin analog) and semaglutide (GLP-1 agonist). Studied for dual-pathway satiety signaling and metabolic regulation surpassing single-agent approaches.
This compound belongs to the metabolic category of research peptides and has been the subject of numerous preclinical investigations. Its unique molecular properties make it a valuable tool for researchers exploring novel therapeutic pathways.
CagriSema combines two distinct mechanisms: cagrilintide is a long-acting amylin analog that activates amylin and calcitonin receptors in the area postrema and nucleus tractus solitarius, modulating satiety signaling and slowing gastric emptying. Semaglutide activates GLP-1 receptors, enhancing glucose-dependent insulin secretion and central satiety signaling. The dual agonism produces additive effects on energy intake reduction and glycaemic control that exceed either agent alone in preclinical and clinical models. The growing body of published literature continues to expand our understanding of this compound's potential applications in laboratory settings.
Mechanism of Action
CagriSema combines two distinct mechanisms: cagrilintide is a long-acting amylin analog that activates amylin and calcitonin receptors in the area postrema and nucleus tractus solitarius, modulating satiety signaling and slowing gastric emptying. Semaglutide activates GLP-1 receptors, enhancing glucose-dependent insulin secretion and central satiety signaling. The dual agonism produces additive effects on energy intake reduction and glycaemic control that exceed either agent alone in preclinical and clinical models.
The signaling pathways activated by CagriSema continue to be mapped through proteomic and transcriptomic analyses. Current research focuses on identifying the specific receptor subtypes and downstream effectors responsible for the observed biological responses. Understanding these molecular interactions is critical for advancing the compound from preclinical investigation toward potential translational applications.
Research Areas
- Metabolic pathway regulation research
- Glucose homeostasis and insulin sensitivity
- Energy expenditure and lipid metabolism
- Satiety signaling mechanisms
- Metabolic flux analysis
Compound Specifications
| CAS Number | 2601842-66-4 · 910463-68-2 |
| Purity | ≥98% HPLC-MS verified |
| Storage | −20 °C lyophilised. 2–8 °C after dissolution, ≤14 days. |
| Category | Metabolic |
| Price | €145 |
| Format | 5mg lyophilised |
Available Formats
- 3mg vial
- 5mg vial
Dissolution
Use our dilution calculator for precise concentration calculations.